Insmed (INSM)

Insmed (INSM) Income Statement


Insmed Income Statement

Last quarter (Q3 2023), Insmed's total revenue was $79.07M, an increase of 16.75% from the same quarter last year. In Q3, Insmed's net income was $-158.93M. See Insmed’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 280.81M$ 245.36M$ 188.46M$ 164.41M$ 136.47M$ 9.84M
Cost of Revenue
$ 60.20M$ 55.13M$ -44.15M$ 39.87M$ 24.21M$ 2.42M
Gross Profit
$ 220.62M$ 190.23M$ 144.31M$ 124.54M$ 112.25M$ 7.41M
Operating Expense
$ 892.25M$ 668.36M$ 512.07M$ 389.77M$ 347.50M$ 314.75M
Operating Income
$ -680.63M$ -457.32M$ -367.76M$ -265.23M$ -235.25M$ -307.34M
Net Non Operating Interest Income Expense
$ -77.36M$ -26.45M$ -40.47M$ -29.56M$ -27.70M$ -25.47M
Other Income Expense
$ -27.04M$ -24.42M$ 28.18M$ 2.11M$ 9.39M$ 8.73M
Pretax Income
$ -721.95M$ -480.15M$ -436.41M$ -292.69M$ -253.56M$ -324.08M
Tax Provision
$ 1.58M$ 1.38M$ -1.76M$ 1.40M$ 777.00K$ 201.00K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -723.60M$ -481.53M$ -434.65M$ -294.09M$ -254.34M$ -324.28M
Basic EPS
$ -5.28$ -3.91$ -3.88$ -3.01$ -3.01$ -4.22
Diluted EPS
$ -5.28$ -3.91$ -3.88$ -3.01$ -3.01$ -4.22
Basic Average Shares
$ 539.84M$ 123.03M$ 112.11M$ 97.61M$ 84.56M$ 76.89M
Diluted Average Shares
$ 539.84M$ 123.03M$ 112.11M$ 97.61M$ 84.56M$ 76.89M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 952.45M$ 723.48M$ 467.92M$ 429.64M$ 371.71M$ 317.17M
Net Income From Continuing And Discontinued Operation
$ -723.59M$ -481.53M$ -434.65M$ -294.09M$ -254.34M$ -324.28M
Normalized Income
$ -295.61M$ -400.12M-$ -295.33M$ -264.26M$ -332.41M
Interest Expense
---$ 28.17M$ 26.31M$ 24.07M
$ -644.59M$ -453.70M$ -395.94M$ -264.52M$ -227.25M$ -300.00M
$ -627.88M$ -437.42M$ -378.79M$ -250.37M$ -217.07M$ -295.18M
Currency in USD

Insmed Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis